Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor
Masaki Yamaguchi, Saori Munemoto, Atsuo Kasada, Ryoichi Murata, Mikio Ueda
20100801
2010 Sept 1
Leuk Res
Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor
Leuk Res. 2010 Sept;34(9), Masaki Yamaguchi, Saori Munemoto, Atsuo Kasada, Ryoichi Murata, Mikio Ueda
1IntroductionImatinib mesylate (IM) has been shown to be very beneficial for the treatment of Philadelphia chromosome-positive (Ph-positive) chronic myelogenous leukemia (CML) in chronic phase (CP) [1]. Although IM may be effective at all disease stages, the probability of a response decreases and the duration of the response becomes shorter as the disease progresses [2]. Megakaryoblastic crisis of CML is extremely rare, and has a dismal prognosis [3,4]. The prognosis of patients with CML who develop...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
